The NuvoAir House platform contains Air Subsequent, a licensed bluetooth spirometer, a related affected person app and a healthcare portal.
WHY IT MATTERS
Sufferers can use the platform to self-monitor their respiratory well being and share clinically related knowledge with their care groups, who can view this knowledge remotely by way of a healthcare portal.
NuvoAir analytics assist to evaluate modifications within the respiratory standing of every affected person, enabling medical groups to follow-up with their sufferers.
NuvoAir House has been proven to help efficient digital healthcare consultations. The outcomes of a current survey performed by the Cystic Fibrosis Middle at Royal Brompton and Harefield NHS Belief confirmed that utilizing NuvoAir House mixed with digital consultations lowered the variety of hospital visits over a six month interval.
This might doubtlessly result in vital price financial savings for each the sufferers and hospital and cut back the an infection danger for this weak inhabitants through the COVID-19 pandemic.
THE LARGER CONTEXT
In April 2018, NuvoAir unveiled its latest model of its home-use spirometer, dubbed the Air Subsequent, which additionally obtained a CE Mark as a Class lla medical machine.
Earlier this 12 months, the corporate picked up its first FDA 510(ok) for the spirometer machine, which is designed for sufferers with bronchial asthma, COPD or cystic fibrosis.
Across the identical time, the respiratory firm partnered with Roche Italy to make its expertise obtainable in chosen cystic fibrosis centres.
ON THE RECORD
Lorenzo Console, CEO of Stockholm-based NuvoAir, mentioned: “This clearance is a vital stepping stone in our journey to turn into the respiratory platform of alternative for sufferers and physicians. By having the complete platform cleared, NuvoAir can now broaden its providing significantly to incorporate different clinically related digital biomarkers, growing our capacity to know when sufferers’ respiratory well being is deteriorating.”